How is Ozempic dosed?
The prescribing information’s own escalation schedule, the trials it cites, its boxed warning and adverse-event tables, and how research-grade semaglutide relates to the branded product — every figure attributed to where it was read.
Topic: Reading Ozempic’s FDA prescribing information
Audience: Anyone comparing a dosing schedule against its source
Reading time: 7–9 minutes
Not affiliated with Novo Nordisk. Prof. Peptide is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Ozempic is a registered trademark of Novo Nordisk A/S. This page reports what Novo Nordisk’s own prescribing information and FDA’s own publications state; it does not sell, ship, or recommend the branded product.
On this page
What Ozempic is
Ozempic is a brand name. Its active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk. The label states Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Semaglutide is also sold under other brand names, at different doses, for different indications — Wegovy (chronic weight management) and Rybelsus (an oral form, type 2 diabetes only) are the same molecule with different labels. The Prof. Peptide semaglutide profile covers how the three relate, the mechanism, and the published trial evidence across all three. This page reads Ozempic’s own label specifically, since its dosing schedule, indications, and cited trials are not identical to Wegovy’s or Rybelsus’s.
What the label specifies
The table below is Ozempic’s recommended dosage as stated in section 2.2 of its prescribing information — Novo Nordisk, OZEMPIC (semaglutide) injection prescribing information, DailyMed setid adec4fd2-6858-4c99-91d4-531f5f2a2d79, effective May 19, 2026.
| Step | Dosage | As specified by the label |
|---|---|---|
| Initiation | 0.25 mg once weekly | For 4 weeks. The label states this dosage is to reduce the risk of gastrointestinal adverse reactions during initiation, not for glycemic control. |
| First increase | 0.5 mg once weekly | After 4 weeks on the 0.25 mg dosage. |
| Second increase (if needed) | 1 mg once weekly | After at least 4 weeks on the 0.5 mg dosage, if additional glycemic control is needed. |
| Maximum dosage (if needed) | 2 mg once weekly | After at least 4 weeks on the 1 mg dosage, if additional glycemic control is needed. |
| Chronic kidney disease maintenance | 1 mg once weekly | After at least 4 weeks on the 0.5 mg dosage — the label states this dosage specifically to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in patients with type 2 diabetes and chronic kidney disease. |
The label states the maximum recommended dosage is 2 mg once weekly. Section 2.1 instructs that a missed dose be administered within 5 days; past that window, the label instructs skipping the missed dose and resuming the regular weekly schedule. Section 2.1 also instructs subcutaneous injection in the abdomen, thigh, or upper arm, with a different site used each week within the same body region.
Dosage forms and strengths (section 3) list single-patient-use pens and single-dose prefilled syringes at 0.25 mg, 0.5 mg, 1 mg, and 2 mg per injection — the label’s strengths are per-injection doses delivered by a pre-filled device, so the label states no reconstitution math anywhere. The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.
What the trials administered
Section 14 of the label (Clinical Studies) names the trials behind Ozempic’s approved indications. The three below are the ones the label cites by name and registry number for the dosing and outcomes discussed on this page. Each is graded against Prof. Peptide’s standing citation convention — a claim is attributed when a marker resolves to a named, checkable primary source, rather than left as an unmarked figure. All three grade as attributed: each is named in the label itself, with a registry number checkable against ClinicalTrials.gov independent of the label.
Monotherapy trial (NCT02054897)
30-week, double-blind, placebo-controlled
Arms: Placebo (N=129), OZEMPIC 0.5 mg (N=128), OZEMPIC 1 mg (N=130) — patients with type 2 diabetes inadequately controlled by diet and exercise
Endpoint reported: Change in HbA1c from baseline at week 30: −0.1% (placebo) vs. −1.4% (0.5 mg) vs. −1.6% (1 mg); difference from placebo statistically significant at p<0.0001 for both doses.
Attributed — cited directly in the label's own Clinical Studies section (14.1), primary source open below.
SUSTAIN 6 (NCT01720446)
Multi-center, multi-national, placebo-controlled, double-blind cardiovascular outcomes trial
Arms: Placebo (N=1,649), OZEMPIC (N=1,648) — patients with type 2 diabetes and established atherosclerotic cardiovascular disease, median observation 2.1 years
Endpoint reported: Hazard ratio for time to first major adverse cardiovascular event (MACE — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke): 0.74 (95% CI: 0.58, 0.95) vs. placebo.
Attributed — cited directly in the label's Clinical Studies section (14.2) and in the boxed indication for cardiovascular risk reduction.
FLOW (NCT03819153)
Placebo-controlled kidney and cardiovascular outcomes trial
Arms: Placebo (N=1,766), OZEMPIC 1 mg (N=1,767) — patients with type 2 diabetes and chronic kidney disease
Endpoint reported: Hazard ratio for the composite endpoint (≥50% sustained eGFR decline, sustained eGFR <15 mL/min/1.73m², chronic renal replacement therapy, or renal/cardiovascular death): 0.76 (95% CI: 0.66, 0.88), p=0.0003.
Attributed — cited directly in the label's Clinical Studies section and underlying the kidney-disease indication added to the label, with a registry number checkable against ClinicalTrials.gov independent of the label.
Wegovy’s label cites a different trial program (the STEP trials, for chronic weight management) at different doses and a different indication. Those figures belong to Wegovy’s own label, not Ozempic’s, even though both products share the same active ingredient — the semaglutide profile covers the STEP program directly.
The label’s warnings and adverse events
Boxed warning: risk of thyroid C-cell tumors
The label states: “In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.”
The label states Ozempic is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and instructs counseling patients on the potential risk and on symptoms such as a mass in the neck, dysphagia, dyspnea, or persistent hoarseness.
Section 6 of the label lists eight other warnings discussed elsewhere in the prescribing information: acute pancreatitis, diabetic retinopathy complications, hypoglycemia with concomitant insulin secretagogues or insulin, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation. The label states the most common adverse reactions reported in ≥5% of Ozempic-treated patients are nausea, vomiting, diarrhea, abdominal pain, and constipation.
Table 1 of the label reports adverse reaction rates from two placebo-controlled trials (521 patients, mean exposure 32.9 weeks), for reactions occurring in ≥5% of Ozempic-treated patients:
| Adverse reaction | Placebo (N=262) | Ozempic 0.5 mg (N=260) | Ozempic 1 mg (N=261) |
|---|---|---|---|
| Nausea | 6.1% | 15.8% | 20.3% |
| Vomiting | 2.3% | 5% | 9.2% |
| Diarrhea | 1.9% | 8.5% | 8.8% |
| Abdominal pain | 4.6% | 7.3% | 5.7% |
| Constipation | 1.5% | 5% | 3.1% |
Compounding and research-grade semaglutide
Ozempic’s prescribing information does not mention compounding. The word does not appear anywhere in the label. Everything above this section describes a prescription drug product, manufactured by Novo Nordisk and dispensed by a pharmacy against a prescription.
Research-grade semaglutide, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is neither the branded product described above nor a pharmacy-compounded version of it. It is sold labeled for research use, not for human administration, and it is not dispensed against a prescription.
Separately from the branded label, FDA has published its own position on compounded semaglutide. Its April 1, 2026 statement on compounding, once the national GLP-1 supply stabilized, describes the conditions under which a compounded drug can lawfully be exempt under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and states FDA’s position that a compounded product is treated as an unlawful copy of a commercially available drug when it shares the same active ingredient, a similar or easily substitutable strength, and the same route of administration — unless a prescriber documents a significant difference for an individual patient.
On April 30, 2026, FDA announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, stating it “did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances.” The public comment period on that proposal closed; as of this page’s last check, FDA had not published a final determination.
None of this changes what the label above states, and none of it describes Prof. Peptide’s vendors as compounding pharmacies — they are not. It is published here because a reader comparing a branded dosing schedule against a research-grade product should be able to see, in one place, that the two are governed by different rules, and that the regulatory status of compounded semaglutide is itself unsettled and separate from both.
FAQ
Is Ozempic the same as semaglutide?
What is the starting dose on the Ozempic label?
What is the maximum Ozempic dose?
What happens if a dose is missed?
Does Ozempic carry a boxed warning?
Is compounded or research-grade semaglutide the same as Ozempic?
References
- Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information. DailyMed, setid adec4fd2-6858-4c99-91d4-531f5f2a2d79, effective 2026-05-19. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug Alerts and Statements, 2026-04-01. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Press Announcements, 2026-04-30. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6, NCT01720446). N Engl J Med. 2016;375:1834-1844. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
- ClinicalTrials.gov. Monotherapy trial of once-weekly semaglutide in type 2 diabetes, NCT02054897. https://clinicaltrials.gov/study/NCT02054897
- ClinicalTrials.gov. Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease (FLOW), NCT03819153. https://clinicaltrials.gov/study/NCT03819153
We may earn commissions from peptide vendor affiliate links.